Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Vitamin D  COVID-19 treatment studies for Vitamin D  C19 studies: Vitamin D  Vitamin D   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Death at day 26 71% Improvement Relative Risk Death at day 10 90% c19early.org/d Carpagnano et al. Vitamin D for COVID-19 Sufficiency Are vitamin D levels associated with COVID-19 outcomes? Retrospective 42 patients in Italy Lower mortality with higher vitamin D levels (p=0.05) Carpagnano et al., J. Endocrinol. Invest., 2020,.., doi:10.1007/s40618-020-01370-x Favors vitamin D Favors control
Vitamin D deficiency as a predictor of poor prognosis in patients with acute respiratory failure due to COVID-19
Carpagnano et al., J. Endocrinol. Invest., 2020, Aug 9, 1-7, doi:10.1007/s40618-020-01370-x
Carpagnano et al., Vitamin D deficiency as a predictor of poor prognosis in patients with acute respiratory failure due to.., J. Endocrinol. Invest., 2020, Aug 9, 1-7, doi:10.1007/s40618-020-01370-x
Aug 2020   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Retrospective study 42 patients with acute respiratory failure, 81% with low vitamin D levels.
After 10 days, patients with severe vitamin D deficiency had a 50% probability of dying, while those with vitamin D ≥ 10 ng/mL had a 5% mortality risk, RR 0.1, p = 0.019.
risk of death at day 26, 70.6% lower, RR 0.29, p = 0.0499, high D levels 5 of 34 (14.7%), low D levels 4 of 8 (50.0%), NNT 2.8, >30 ng/mL.
risk of death at day 10, 90.0% lower, RR 0.10, p = 0.02, high D levels 2 of 34 (5.9%), low D levels 4 of 8 (50.0%), NNT 2.3, adjusted per study, >30 ng/mL.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Carpagnano et al., 9 Aug 2020, retrospective, Italy, peer-reviewed, 10 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperVitamin DAll
Abstract: Journal of Endocrinological Investigation (2021) 44:765–771 https://doi.org/10.1007/s40618-020-01370-x ORIGINAL ARTICLE Vitamin D deficiency as a predictor of poor prognosis in patients with acute respiratory failure due to COVID‑19 G. E. Carpagnano1 · V. Di Lecce1 · V. N. Quaranta2 · A. Zito3 · E. Buonamico1 G. Di Gioia1 · V. N. Valerio1 · O. Resta1 · E. Capozza1 · A. Palumbo1 · Received: 7 June 2020 / Accepted: 18 July 2020 / Published online: 9 August 2020 © The Author(s) 2020 Abstract Purpose Hypovitaminosis D is a highly spread condition correlated with increased risk of respiratory tract infections. Nowadays, the world is in the grip of the Coronavirus disease 19 (COVID 19) pandemic. In these patients, cytokine storm is associated with disease severity. In consideration of the role of vitamin D in the immune system, aim of this study was to analyse vitamin D levels in patients with acute respiratory failure due to COVID-19 and to assess any correlations with disease severity and prognosis. Methods In this retrospective, observational study, we analysed demographic, clinical and laboratory data of 42 patients with acute respiratory failure due to COVID-19, treated in Respiratory Intermediate Care Unit (RICU) of the Policlinic of Bari from March, 11 to April 30, 2020. Results Eighty one percent of patients had hypovitaminosis D. Based on vitamin D levels, the population was stratified into four groups: no hypovitaminosis D, insufficiency, moderate deficiency, and severe deficiency. No differences regarding demographic and clinical characteristics were found. A survival analysis highlighted that, after 10 days of hospitalization, severe vitamin D deficiency patients had a 50% mortality probability, while those with vitamin D ≥ 10 ng/mL had a 5% mortality risk (p = 0.019). Conclusions High prevalence of hypovitaminosis D was found in COVID-19 patients with acute respiratory failure, treated in a RICU. Patients with severe vitamin D deficiency had a significantly higher mortality risk. Severe vitamin D deficiency may be a marker of poor prognosis in these patients, suggesting that adjunctive treatment might improve disease outcomes. Keywords COVID-19 · Vitamin D deficiency · Acute respiratory failure · Mortality risk G. E. Carpagnano and V. Di Lecce contribuited equally. G. Di Gioia giusdigioia@libero.it * E. Buonamico enricobuonamico@gmail.com G. E. Carpagnano elisiana.carpagnano@uniba.it V. N. Valerio vnvale@tiscali.it V. Di Lecce valentina.dilecce89@gmail.com O. Resta onofrio.resta@uniba.it V. N. Quaranta vitalianonicola.40@gmail.com 1 Institute of Respiratory Disease, Department of Basic Medical Science, Neuroscience, and Sense Organs, University of Bari “Aldo Moro”, piazza Giulio Cesare 11, 70125 Bari, Italy E. Capozza elena.capozza@gmail.com 2 Pneumology Department, “Di Venere” Hospital Bari, Bari, Italy A. Palumbo alessandro.palumbo@policlinico.ba.it 3 Cardiology Department, “SS Annunziata” Hospital, Taranto, Italy A. Zito annapaolazito@yahoo.it 13 Vol.:(0123456789)
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit